• In early February 2026, Illumina reported fourth-quarter 2025 revenue of US$1,159 million and full-year 2025 revenue of US$4.34 billion, issued 2026 revenue guidance of US$4.5–4.6 billion, and closed its SomaLogic acquisition.
• At the same time, Illumina expanded its role in clinical and conservation genomics, including a sequencing agreement for up to 4,000 Frozen Zoo® samples with the San Diego Zoo Wildlife Alliance.
• Now we’ll examine how Illumina’s 2026 guidance, including the SomaLogic contribution, could influence its existing investment narrative and risk balance.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

Illumina Investment Narrative Recap

To hold Illumina today, you need to believe its core sequencing and clinical consumables franchise remains attractive while it integrates SomaLogic and manages end‑market uncertainty. The 2026 revenue guide of US$4.5–4.6 billion, including only a modest SomaLogic lift, does not radically change that picture. Near term, the key potential catalyst is steady clinical consumables demand, while the biggest risk remains pressure on research and international budgets, which could limit instrument and consumables growth.

The Frozen Zoo agreement with the San Diego Zoo Wildlife Alliance fits neatly into Illumina’s push into applied and clinical genomics. While the contract itself is unlikely to move the financial needle, it highlights broader demand for sequencing and multiomic workflows beyond traditional research settings. For investors focused on catalysts, these partnerships help illustrate how Illumina’s technology can support recurring consumables use in newer markets such as conservation and biodiversity research.

Yet while these developments sound encouraging, investors should also be aware of how acquisition integration and execution risks could still...

Illumina's narrative projects $4.8 billion revenue and $873.5 million earnings by 2028. This requires 3.6% yearly revenue growth and an earnings decrease of about $426.5 million from $1.3 billion today.

Uncover how Illumina's forecasts yield a $135.94 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming about US$4.9 billion of revenue and close to US$1.0 billion of earnings by 2028, far above consensus, while also flagging that acquisitions like SomaLogic could backfire. This shows how differently you and other investors might read the same story, and why these new 2026 numbers could shift both the bullish expectations and the concerns about deal integration.

Explore 4 other fair value estimates on Illumina - why the stock might be worth as much as 34% more than the current price!

Build Your Own Illumina Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Illumina research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.

Curious About Other Options?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.